跳至主要内容
临床试验/ISRCTN73380053
ISRCTN73380053已完成2 期

A prospective Multicenter Phase 2/3 Clinical Trial with Sodium Thiosulfate for the Treatment of Calciphylaxis

Dr. F. Köhler Chemie GmbH (Germany)0 个研究点目标入组 5 人开始时间: 2014年9月2日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
5

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. All patients = 18 years
  • 2. Male or female hemodialysis (HD) patients with a diagnosis of calciphylaxis. (Patients on peritoneal dialysis or patients with the requirement for renal replacement therapy, who are diagnosed with calciphylaxis, may be switched to HD and included in the study after switching).
  • 3. Able to understand character and individual consequences of the clinical trial and to provide written informed consent to participate in the study

排除标准

  • Current exclusion criteria as of 09/07/2018:
  • 1. Pregnant or lactating patients. As pregnancy is an extremely rare event in HD patients, a pregnancy test will only be performed in ambiguous cases.
  • 2. Patients who have participated in any other investigational studies within 30 days previous to enrolment
  • 3. History of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or any history of drug abuse or addiction within 12 months of study enrolment
  • 4. Good response to conventional treatment
  • 5. Life expectancy less than 4 months in the judgment of the investigator
  • Previous exclusion criteria:
  • 1. Sodium metabisulfite hypersensitivity, among others the history of bronchial asthma due to known sodium metabisulfite hypersensitivity
  • 2. Pregnant or lactating patients. As pregnancy is an extremely rare event in HD patients, a pregnancy test will only be performed in ambiguous cases.
  • 3. Patients who have participated in any other investigational studies within 30 days previous to enrolment
  • 4. History of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or any history of drug abuse or addiction within 12 months of study enrolment
  • 5. Good response to conventional treatment
  • 6. Life expectancy less than 4 months in the judgment of the investigator

研究者

发起方
Dr. F. Köhler Chemie GmbH (Germany)

相似试验

进行中(未招募)
1 期
Phase 2/3 Clinical Trial with Sodium Thiosulfate for the Treatment of CalciphylaxisCalciphylaxisMedDRA version: 20.0Level: PTClassification code 10051714Term: CalciphylaxisSystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2014-002128-28-ATDr. F. Köhler Chemie GmbH40
进行中(未招募)
1 期
Phase 2/3 Clinical Trial with Sodium Thiosulfate for the Treatment of CalciphylaxisCalciphylaxisMedDRA version: 20.0Level: PTClassification code 10051714Term: CalciphylaxisSystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2014-002128-28-DEDr. F. Köhler Chemie GmbH40
进行中(未招募)
1 期
Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) after preoperative chemotherapy in patients with peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junctioPeritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junctionMedDRA version: 20.0Level: LLTClassification code 10042080Term: Stomach cancerSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10042081Term: Stomach cancer in situSystem Organ Class: 100000004864
EUCTR2006-006088-22-DEKlinik für Chirurgie, Charité Campus Virchow-Klinikum180
已完成
3 期
Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC)after preoperative chemotherapy in patients with peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junctioMedDRA - 10042080 (stomach cancer)C16D00.2C78.6C79Malignant neoplasm of stomachStomachSecondary malignant neoplasm of retroperitoneum and peritoneumSecondary malignant neoplasm of other and unspecified sites
DRKS00003078Charité Campus Charité Mitte105
尚未招募
3 期
REALISE: Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and EffectivenessSoil-transmitted helminthsPaediatrics
PACTR202402529220760aboratorios Liconsa SA20,000